Evidence-base for aspirin as venous thromboembolic prophylaxis following joint replacement.

New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism. Ther Clin Risk Manag (2015) 0.77

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (2002) 20.22

Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.88

Mortality and implant revision rates of hip arthroplasty in patients with osteoarthritis: registry based cohort study. BMJ (2012) 5.71

Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med (2009) 4.91

Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med (2011) 2.80

Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study. J Bone Joint Surg Br (2005) 2.71

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med (2001) 2.54

Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med (1991) 1.81

Enhanced recovery program for hip and knee replacement reduces death rate. Acta Orthop (2011) 1.73

Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am (2001) 1.71

Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med (1977) 1.65

De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet (2008) 1.57

Compliance with Surgical Care Improvement Project measures and hospital-associated infections following hip arthroplasty. J Bone Joint Surg Am (2012) 1.50

Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty. J Bone Joint Surg Am (2013) 1.44

Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. Br Med J (1980) 1.37

A financial analysis of revision hip arthroplasty: the economic burden in relation to the national tariff. J Bone Joint Surg Br (2012) 1.27

Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study. J Bone Joint Surg Br (2011) 1.15

Meta-analysis of cause of death following total joint replacement using different thromboprophylaxis regimens. J Bone Joint Surg Br (2012) 1.07

Duration of the increase in early postoperative mortality after elective hip and knee replacement. J Bone Joint Surg Am (2010) 1.07

Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty (2009) 1.07

Prevention of deep vein thrombosis after major knee surgery--a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost (1992) 1.05

Reduced short-term complications and mortality following Enhanced Recovery primary hip and knee arthroplasty: results from 6,000 consecutive procedures. Acta Orthop (2013) 1.02

Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty. J Bone Joint Surg Am (2012) 1.00

The incidence of fatal pulmonary embolism after primary hip and knee replacement in a consecutive series of 4253 patients. J Bone Joint Surg Br (2009) 0.97

Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br (2012) 0.96

Patient reported outcome measures after revision of the infected TKR: comparison of single versus two-stage revision. Knee Surg Sports Traumatol Arthrosc (2012) 0.95

Thromboembolic prophylaxis in total joint arthroplasty. Thrombosis (2012) 0.87

The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National Joint Registry. J Bone Joint Surg Br (2011) 0.86

Pneumatic sequential-compression boots compared with aspirin prophylaxis of deep-vein thrombosis after total knee arthroplasty. J Bone Joint Surg Am (1990) 0.85

The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after knee replacement: a non-randomised comparison using National Joint Registry Data. J Bone Joint Surg Br (2012) 0.81

Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am (1991) 0.80

Ulceration of the lower leg after total knee replacement a five-year review. J Bone Joint Surg Br (2001) 0.80

Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement. A randomized trial. The German Hip Arthroplasty Trial (GHAT) Group. Arch Orthop Trauma Surg (1992) 0.79

Low-dose heparin and deep-vein thrombosis after total hip replacement. Thromb Haemost (1976) 0.78

Patient-reported history of leg ulceration 12-16 years after total primary knee or hip replacement. Acta Orthop (2011) 0.77